Genzyme And Osiris Partner To Develop And Commercialize First-In-Class Adult Stem Cell Products Genzyme Corp. (Nasdaq: GENZ) and Osiris Therapeutics (Nasdaq: OSIR) announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases. These stem-cell products are designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation.
Source: www.medicalnewstoday.comOncolytics Biotech Inc. Announces Decision To Pursue Phase II/III Pivotal Clinical Trial Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that it has made a decision to pursue a pivotal (Phase II/III) randomized trial using the combination of REOLYSIN(R) with paclitaxel/carboplatin in refractory patients with head and neck cancers. The decision was made following a review of results by the Company's Board of Directors from the Company's ongoing U.K.
Source: www.medicalnewstoday.comNicOx Announces Favorable Blood Pressure Data For Naproxcinod In A Large ABPM Study NicOx S.A. (Euronext Paris: COX) announced positive top-line results from a 118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111 study), which compared the 24-hour blood pressure profile of escalating doses of naproxcinod and naproxen in osteoarthritis (OA) patients with controlled hypertension.
Source: www.medicalnewstoday.comNew Drug Stopped Mice Putting On Weight A European and American study on a new synthetic drug found that it protected laboratory mice from diet-induced obesity and its potential consequences like glucose intolerance and insensitivity to insulin by activating an enzyme that promoted fat consumption and exercise endurance, leading to suggestions that it could be an important new weapon in the fight against obesity and diabetes.
Source: www.medicalnewstoday.comSanvar(R) (Debio 8609) For Esophageal Variceal Bleeding Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced that Debiovision Inc., its Canadian affiliate, filed its Complete Response to the approvable letter received from the United States (U.S.) Food and Drug Administration (FDA) for Sanvar(R), or Debio 8609 (vapreotide acetate).
Source: www.medicalnewstoday.comSupreme Court Hears Opening Arguments In Wyeth V. Levine; Some Appear To Support Limited Pre-Emption The U.S. Supreme Court on Monday heard opening arguments in Wyeth v. Levine, a case that could determine whether patients have the ability to file product liability lawsuits against pharmaceutical companies in state courts, the
Source: www.medicalnewstoday.com
# posted by Network @ 2:00 PM
